scholarly journals Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis

2012 ◽  
Vol 31 (1) ◽  
Author(s):  
Kazuhiro Imai ◽  
Yoshihiro Minamiya ◽  
Souichi Koyota ◽  
Manabu Ito ◽  
Hajime Saito ◽  
...  
Keyword(s):  
Lymph Node ◽  
Dendritic Cell ◽  
Growth Factor ◽  
Lymph Node Metastasis ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Node Metastasis ◽  
Dendritic Cell Migration ◽  
Draining Lymph Node ◽  
Tumor Draining Lymph Node

scholarly journals Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Xia Liu ◽  
Xiuming Tang ◽  
Shaoyan Zhang ◽  
Yun Wang ◽  
Xiaofeng Wang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Growth Factor ◽  
Lymph Node Metastasis ◽  
Gastric Carcinoma ◽  
Tumor Invasion ◽  
Transforming Growth Factor ◽  
Methylation Rate ◽  
Gastric Carcinomas ◽  
Node Metastasis ◽  
Significant Difference

Background. Retinoblastoma (RB) and transforming growth factor-β1 (TGF-β1) are important tumor-related factors.Methods. A series of 30 EBV-associated gastric carcinoma (EBVaGC) and 38 matched EBV-negative gastric carcinoma (EBVnGC) tissues were examined for the promoter methylation ofRBby methylation-specific PCR (MSP) method. The expression ofRBandTGF-β1in gastric carcinoma tissues was detected by immunohistochemistry.Results. The methylation rate ofRBgene in EBVaGC and EBVnGC was 80.0% (24/30) and 50.0% (19/38), respectively. The difference ofRBmethylation rate between EBVaGC and EBVnGC was significant(χ2=6.490,  P=0.011). There was no significant difference forRBexpression between EBVaGC (43.3%, 13/30) and EBVnGC (63.2%, 24/38), and also forTGF-β1between EBVaGC (56.7%, 17/30) and EBVnGC (63.2%, 24/38).RBmethylation was not reversely correlated withRBexpression in gastric carcinoma tissues(χ2=2.943,  P=0.086,  r=0.208).RBmethylation, loss expression ofRB, andTGF-β1expression were significantly associated with tumor invasion and lymph node metastasis (P<0.05), but was not associated with sex, age, histological subtype (differentiation status) and tumor location.Conclusions. Methylation ofRBis a common event in gastric carcinomas and EBV induces methylation ofRBin EBVaGC, which may contribute to the development of gastric carcinomas. EBV has no significant effect on induction ofTGF-β1expression. Detection ofRBmethylation,RBexpression, andTGF-β1expression may be helpful to judge the status of tumor invasion and lymph node metastasis in gastric carcinomas.

scholarly journals Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252646
Author(s):  
Margot Geens ◽  
Sofie Stappers ◽  
Heleen Konings ◽  
Benedicte Y. De Winter ◽  
Pol Specenier ◽  
...  
Keyword(s):  
Lymph Node ◽  
Growth Factor ◽  
Lymph Node Metastasis ◽  
Epidermal Growth Factor ◽  
Healthy Volunteers ◽  
Control Group ◽  
Node Metastasis ◽  
Oncological Patients ◽  
Platinum Based Chemotherapy ◽  
Epidermal Growth

In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF could serve as a prognostic marker of survival and as a predictive marker for treatment response to platinum-based chemotherapy. A total of 59 oncological patients and a control group of age- and sex-matched healthy volunteers were included in this study. Pre-treatment serum EGF from both groups was determined. Patient’s and tumour characteristics and mortality were recorded during a 5-year follow up period. Baseline serum EGF significantly differed between the oncological patients and the healthy volunteers (p<0.001). Serum EGF was associated with lymph node metastasis (p = 0.004) but not with sex (p = 0.753), age (p = 1.00), TNM stage (p = 0.191) or tumour size (p = 0.077). Neither serum EGF (p = 0.81) nor age (p = 0.55) showed an effect on the patient’s survival. Tumour location was significantly associated with overall 5-year survival (p = 0.003). The predictive capacity of serum EGF of response to chemotherapy was limited (AUC = 0.606), a sensitivity of 80% and a specificity of 56% was observed resulting in a likelihood ratio of a positive and negative test equal to 1.81 and 0.36, respectively. In conclusion, serum EGF levels are 5.5 times higher in an oncological population compared to a control group. Within the oncological population, low serum EGF values are associated with the presence of lymph node metastasis. Further investigation is necessary to determine if the serum EGF levels could serve as a diagnostic biomarker.

Sign in / Sign up

Export Citation Format

Share Document